nach oben

Annals of Hematology

Erschienen in:

03.10.2017 | Letter to the Editor

PET-positive bone lesion due to Langerhans cell histiocytosis after BEACOPP therapy for Hodgkin lymphoma: how anamnesis, histopathological accuracy, and molecular analysis could resolve a clinical dilemma

verfasst von: Simon Haefliger, Michel Bihl, Fatime Krasniqi, Alexandar Tzankov

Erschienen in: Annals of Hematology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Excerpt

Dear Editor, …

Berres ML, Merad M, Allen CE (2015) Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X? Br J Haematol 169:3–13. https://doi.org/10.1111/bjh.13247 CrossRefPubMed

Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, Kuo FC, Ligon AH, Stevenson KE, Kehoe SM, Garraway LA, Hahn WC, Meyerson M, Fleming MD, Rollins BJ (2010) Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 116:1919–1923. https://doi.org/10.1182/blood-2010-04-279083 CrossRefPubMedPubMedCentral

Brown NA, Furtado LV, Betz BL, Kiel MJ, Weigelin HC, Lim MS, Elenitoba-Johnson KS (2014) High prevalence of somatic MAP2K1 mutations in BRAF V600E–negative Langerhans cell histiocytosis. Blood 124:1655–1658. https://doi.org/10.1182/blood-2014-05-577361 CrossRefPubMed

Pina-Oviedo S, Medeiros LJ, Li S, Khoury JD, Patel KP, Alayed K, Cason RC, Bowman CJ, Yin CC (2017) Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations. Mod Pathol 30:734–744. https://doi.org/10.1038/modpathol.2016.235 CrossRefPubMed

Christie LJ, Evans AT, Bray SE, Smith ME, Kernohan NM, Levison DA, Goodlad JR (2006) Lesions resembling Langerhans cell histiocytosis in association with other lymphoproliferative disorders: a reactive or neoplastic phenomenon? Hum Pathol 37:32–39. https://doi.org/10.1016/j.humpath.2005.08.024 CrossRefPubMed

Mesguich C, Cazeau AL, Bouabdallah K, Soubeyran P, Guyot M, Milpied N, Bordenave L, Hindié E (2016) Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation. Br J Haematol 175:652–660. https://doi.org/10.1111/bjh.14292 CrossRefPubMed

Naumann R, Beuthien-Baumann B, Fischer R, Kittner T, Bredow J, Kropp J, Ockert D, Ehninger G (2002) Simultaneous occurrence of Hodgkin’s lymphoma and eosinophilic granuloma: a potential pitfall in positron emission tomography imaging. Clin Lymphoma Myeloma Leuk 3:121–124. https://doi.org/10.3816/CLM.2002.n.019 CrossRef

Shin MS, Buchalter SE, Ho KJ (1994) Langerhans cell histiocytosis associated with Hodgkin’s disease: a case report. J Natl Med Assoc 86:65–69PubMedPubMedCentral

Egeler RM, Neglia JP, Arico M, Favara BE, Heitger A, Nesbit ME, Nicholson HS (1998) The relation of Langerhans cell histiocytosis to acute leukaemia, lymphomas, and other solid tumors. The LCH-Malignancy Study Group of the Histiocyte Society Hematol Oncol Clin North Am 12:369–378. https://doi.org/10.1016/S0889-8588(05)70516-5 CrossRef

10.

Natoli A, Lüpertz R, Merz C, Müller WW, Köhler R, Krammer PH, Li-Weber M (2013) Targeting the IL-4/IL-13 signaling pathway sensitizes Hodgkin lymphoma cells to chemotherapeutic drugs. Int J Cancer 133:1945–1954. https://doi.org/10.1002/ijc.28189 CrossRefPubMed

11.

Loghavi S, Khoury JD (2017) Langerhans cell histiocytosis in a patient with hairy cell leukemia: a tale of divergence. Blood 129:1563. https://doi.org/10.1182/blood-2016-11-749374 CrossRefPubMed

12.

Ryland GL, Jones K, McBean M, Khot A, Seymour JF, Blombery P (2017) Comprehensive genomic characterization dissects the complex biology of a case of synchronous Burkitt lymphoma and myeloid malignancy with shared hematopoietic ancestry. Leuk Lymphoma 9:1–4. https://doi.org/10.1080/10428194.2017.1361029 CrossRef

Titel: PET-positive bone lesion due to Langerhans cell histiocytosis after BEACOPP therapy for Hodgkin lymphoma: how anamnesis, histopathological accuracy, and molecular analysis could resolve a clinical dilemma
verfasst von: Simon Haefliger
Michel Bihl
Fatime Krasniqi
Alexandar Tzankov
Publikationsdatum: 03.10.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 2/2018
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-017-3145-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Parodontalbehandlung verbessert Prognose bei Katheterablation

18.04.2024 | Arterielle Hypertonie | Nachrichten

Antihypertensiva schützen auch alte Menschen noch vor Demenz

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

17.04.2024 | DGIM 2024 | Nachrichten

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

HCV load as a possible prognostic factor in patients with HCV-related DLBCL

Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens

Systemic trichosporonosis mimicking disseminated varicella zoster viral infection during blinatumomab therapy

Phenotype-based gene analysis allowed successful diagnosis of X-linked neutropenia associated with a novel WASp mutation

PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas

R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience